<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880931</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0239</org_study_id>
    <nct_id>NCT01880931</nct_id>
  </id_info>
  <brief_title>The Effect Site Concentration of Remifentanil for Preventing QTc Interval Prolongation During Intubation in Normotensive and Hypertensive Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out the effect site concentration of remifentanil for preventing QTc interval
      prolongation during intubation under propofol-remifentanil anesthesia in normotensive and
      hypertensive patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that anesthetic agents can influence the QTc. In addition, tracheal intubation
      during induction can stimulates sympathetic activity, which, as a results, prolong the QTc
      interval. Therefore, the aim of study is to find out the effect site concentration of
      remifentanil for preventing QTc interval prolongation during intubation under
      propofol-remifentanil anesthesia in normotensive and hypertensive patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect site concentration of remifentanil for preventing QTc interval prolongation</measure>
    <time_frame>2 min</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Intubation, Intratracheal</condition>
  <arm_group>
    <arm_group_label>Normotensive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To find out the effect site concentration of remifentanil for preventing QTc prolongation &lt; 15 sec during intubation : Dixon's up-and-down method</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To find out the effect site concentration of remifentanil for preventing QTc prolongation &lt; 15 sec during intubation : Dixon's up-and-down method</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>The effect site concentration of remifentanil</description>
    <arm_group_label>Normotensive patients</arm_group_label>
    <arm_group_label>Hypertensive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 50 years ASA class I-II female who received surgery with endotracheal intubation

        Exclusion Criteria:

          -  emergency surgery electrocardiography abnormality diabetes mellitus end stage renal
             disease moderate to severe cardiac disease moderate to severe liver dysfunction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>So Yeon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2013</study_first_submitted>
  <study_first_submitted_qc>June 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Severance Hospital</investigator_affiliation>
    <investigator_full_name>So Yeon Kim</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

